{"id":"bnt162b4-10-mcg","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pain medications","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelets","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Corticosteroids","action":"Avoid","effect":"Decreased immune response"},{"drug":"Immunosuppressants","action":"Avoid","effect":"Decreased immune response"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased immune response"},{"drug":"Interferons","action":"Avoid","effect":"Decreased immune response"},{"drug":"Thalidomide","action":"Avoid","effect":"Decreased immune response"}],"commonSideEffects":[],"contraindications":["There is no information provided on contraindications for BNT162b4 10 mcg in the given text."],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bnt162b4-10-mcg","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:36:53.760006+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:36:59.463932+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:36:53.828558+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b4-10-mcg","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:36:59.776484+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tubulin inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:01.570367+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL39541/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:01.220275+00:00"}},"allNames":"bnt162b4 10 mcg","offLabel":[],"timeline":[],"aiSummary":"Pfizer's BNT162b4 10 mcg is a marketed COVID-19 prevention drug. It is developed by Pfizer Inc. The mechanism of action is not specified. BNT162b4 10 mcg is primarily used for COVID-19 prevention. It has significant commercial value with revenue of 63.6B. There are no pipeline developments mentioned. The drug's clinical differentiation is not provided.","brandName":"BNT162b4 10 mcg","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Unknown","modality":"Unknown","drugClass":"Unknown","explanation":"","oneSentence":"","technicalDetail":"The exact mechanism of action for BNT162b4 10 mcg is unknown. Further research is needed to determine how this drug interacts with the body's biological systems. This lack of information may limit its use in clinical settings."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$0","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b4-10-mcg","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:05.843497+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Comirnaty (BNT162b2)","company":"Pfizer","advantage":"Comirnaty (BNT162b2) is another mRNA vaccine developed by Pfizer and BioNTech, competing with BNT162b4 in the COVID-19 vaccine market."},{"name":"Covaxin","company":"Bharat Biotech","advantage":"Covaxin is an inactivated whole virus COVID-19 vaccine, competing with BNT162b4 in terms of vaccine type and target market."},{"name":"AstraZeneca COVID-19 Vaccine (Covishield)","company":"AstraZeneca","advantage":"AstraZeneca COVID-19 Vaccine (Covishield) is a viral vector-based COVID-19 vaccine, competing with BNT162b4 in terms of vaccine type and target market."},{"name":"Johnson & Johnson COVID-19 Vaccine (Ad26.COV2.S)","company":"Johnson & Johnson","advantage":"Johnson & Johnson COVID-19 Vaccine (Ad26.COV2.S) is a viral vector-based COVID-19 vaccine, competing with BNT162b4 in terms of vaccine type and target market."}],"genericName":"bnt162b4-10-mcg","indications":{"approved":[{"name":"COVID-19 prevention","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"BNT162b4 10 mcg","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL39541","moleculeType":"Small molecule","molecularWeight":"785.11"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL39541"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"RNA therapeutics","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:05.843497+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}